Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
Japanese drug makers saw their operating profits soar in FY2015 ended in March, with many delivering record profits as upbeat performances by global brands put a brake on recent downturns in their profit rates. FY2014 earnings suffered one-off drags such…
To read the full story
Related Article
- FY2015 Earnings Roundup - 5: 10 Firms Unveil Mid-Term Biz Plans, Many Play It Safe
June 10, 2016
- FY2015 Earnings Roundup - 4: Generic Biz Strategies Revolving around AG Launches
June 9, 2016
- FY2015 Earnings Roundup - 3: Japan Market Stagnates despite No Drug Price Revision, Off-Patent Brands Weigh
June 8, 2016
- FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
June 7, 2016
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 24, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…